Drug Trial Radar · NCT07545681
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Oct 8, 2027
Study completion Oct 8, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
Conditions
- Malaria, Falciparum
Interventions
GSK3772701 600 mgDrug
A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg.
GSK3772701 900 mgDrug
A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg.
GSK3772701 150 mgDrug
A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule.
GSK3772701 400 mgDrug
A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg.
GSK3772701 50 mgDrug
A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with serious adverse events (SAEs) overall, treatment related, and by severityTime frame: From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)
- Number of participants with non-serious AEs overall, treatment related, and by severityTime frame: From Day 1 up to Day 40
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Lambaréné, Gabon · Recruiting
GSK Investigational Site
Kampala, Tororo, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.